Abstract
Two striking features of human embryonic stem cells that support biological activity are an abbreviated cell cycle and reduced complexity to nuclear organization. The potential implications for rapid proliferation of human embryonic stem cells within the context of sustaining pluripotency, suppressing phenotypic gene expression and linkage to simplicity in the architectural compartmentalization of regulatory machinery in nuclear microenvironments is explored. Characterization of the molecular and architectural commitment steps that license human embryonic stem cells to initiate histone gene expression is providing understanding of the principal regulatory mechanisms that control the G1/S phase transition in primitive pluripotent cells. From both fundamental regulatory and clinical perspectives, further understanding of the pluripotent cell cycle in relation to compartmentalization of regulatory machinery in nuclear microenvironments is relevant to applications of stem cells for regenerative medicine and new dimensions to therapy where traditional drug discovery strategies have been minimally effective.
Keywords: Human embryonic stem cells, reprogrammed pluripotent cells, histone gene expression, nuclear organization, chromatin structure, microenvironments, G1/S phase transition, mitosis, Histone Locus Bodies (HLBs), Endocrinology
Current Pharmaceutical Design
Title:The Architectural Organization of Human Stem Cell Cycle Regulatory Machinery
Volume: 18 Issue: 13
Author(s): Gary S. Stein, Janet L. Stein, Andre van J. Wijnen, Jane B. Lian, Martin Montecino, Ricardo Medina, Kristie Kapinas, Prachi Ghule, Rodrigo Grandy, Sayyed K. Zaidi, Klaus A. Becker
Affiliation:
Keywords: Human embryonic stem cells, reprogrammed pluripotent cells, histone gene expression, nuclear organization, chromatin structure, microenvironments, G1/S phase transition, mitosis, Histone Locus Bodies (HLBs), Endocrinology
Abstract: Two striking features of human embryonic stem cells that support biological activity are an abbreviated cell cycle and reduced complexity to nuclear organization. The potential implications for rapid proliferation of human embryonic stem cells within the context of sustaining pluripotency, suppressing phenotypic gene expression and linkage to simplicity in the architectural compartmentalization of regulatory machinery in nuclear microenvironments is explored. Characterization of the molecular and architectural commitment steps that license human embryonic stem cells to initiate histone gene expression is providing understanding of the principal regulatory mechanisms that control the G1/S phase transition in primitive pluripotent cells. From both fundamental regulatory and clinical perspectives, further understanding of the pluripotent cell cycle in relation to compartmentalization of regulatory machinery in nuclear microenvironments is relevant to applications of stem cells for regenerative medicine and new dimensions to therapy where traditional drug discovery strategies have been minimally effective.
Export Options
About this article
Cite this article as:
Medina, Kristie Kapinas, Prachi Ghule, Rodrigo Grandy, Sayyed K. Zaidi, Klaus A. Becker Gary S. Stein, Janet L. Stein, Andre van J. Wijnen, Jane B. Lian, Martin Montecino, Ricardo, The Architectural Organization of Human Stem Cell Cycle Regulatory Machinery , Current Pharmaceutical Design 2012; 18 (13) . https://dx.doi.org/10.2174/138161212799859639
DOI https://dx.doi.org/10.2174/138161212799859639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice
Current Radiopharmaceuticals Anti-Insulin Receptor Antibodies in the Pathology and Therapy of Diabetes Mellitus
Current Diabetes Reviews Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Recent Patents on Anti-Cancer Drug Discovery Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Ligament and Tendon Repair through Regeneration Using Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design Alginate Bead-Encapsulated PEDF Induces Ectopic Bone Formation In Vivo in the Absence of Co-Administered Mesenchymal Stem Cells
Current Drug Targets Cell Penetrating Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology Calcium Phosphate Materials for Bone Repair Application
Recent Patents on Biomedical Engineering (Discontinued) MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry